Cancer stocks heat up after third big merger in the past month

The third multibillion-dollar buyout of cancer-treatment developers in the past month was a charm for the shares of targeted oncology companies, as Leerink analyst Andrew Berens said Eli Lilly’s deal to buy Loxo Oncology validated the “significant value and interest” in the sector.